The same Spanish group currently conducts a prospective multicenter, randomized, blinded and placebo-controlled, parallel-group, phase IIb/III trial in patients with mild to moderate AD (“Alzheimer’s Management by Albumin Replacement (AMBAR)”). The gene discussed is ALB; the disease is Alzheimer disease.